LON:OXB Oxford Biomedica (OXB) Share Price, News & Analysis GBX 464.50 +6.00 (+1.31%) As of 08/1/2025 12:24 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesBuy This Stock About Oxford Biomedica Stock (LON:OXB) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Oxford Biomedica alerts:Sign Up Key Stats Today's Range 418▼ 464.5050-Day Range 307▼ 464.5052-Week Range 232.50▼ 464.50Volume269,333 shsAverage Volume229,765 shsMarket Capitalization£493.77 millionP/E RatioN/ADividend Yield4.57%Price TargetGBX 390Consensus RatingHold Company Overview Oxford Biomedica (LSE: OXB) is a quality and innovation-led cell and gene therapy CDMO with a mission to enable its clients to deliver life changing therapies to patients around the world. One of the original pioneers in cell and gene therapy, the Company has more than 25 years of experience in viral vectors; the driving force behind the majority of gene therapies. The Company collaborates with some of the world’s most innovative pharmaceutical and biotechnology companies, providing viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV) and adenoviral vectors. Oxford Biomedica’s world-class capabilities span from early-stage development to commercialisation. These capabilities are supported by robust quality-assurance systems, analytical methods and depth of regulatory expertise. Oxford Biomedica, a FTSE4Good constituent, is headquartered in Oxford, UK. It has locations across Oxfordshire, UK and near Boston, MA, US. Learn more at www.oxb.com and follow us on LinkedIn and YouTube. Read More Oxford Biomedica Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks23rd Percentile Overall ScoreOXB MarketRank™: Oxford Biomedica scored higher than 23% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.0 / 5Analyst RatingHold Consensus RatingOxford Biomedica has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageOxford Biomedica has only been the subject of 1 research reports in the past 90 days.Read more about Oxford Biomedica's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Oxford Biomedica is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Oxford Biomedica is -3.45, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioOxford Biomedica has a P/B Ratio of 6.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for OXB. Dividend1.7 / 5Dividend StrengthWeak Dividend LeadershipOxford Biomedica is a leading dividend payer. It pays a dividend yield of 4.57%, putting its dividend yield in the top 25% of dividend-paying stocks.Dividend GrowthOxford Biomedica does not have a long track record of dividend growth.Read more about Oxford Biomedica's dividend. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for OXB. News and Social Media1.8 / 5News Sentiment0.26 News SentimentOxford Biomedica has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Oxford Biomedica this week, compared to 0 articles on an average week. Company Ownership5.0 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Oxford Biomedica insiders have bought more of their company's stock than they have sold. Specifically, they have bought £36,900.36 in company stock and sold GBX 0 in company stock.Percentage Held by Insiders21.17% of the stock of Oxford Biomedica is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions64.13% of the stock of Oxford Biomedica is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Oxford Biomedica's insider trading history. Receive OXB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Oxford Biomedica and its competitors with MarketBeat's FREE daily newsletter. Email Address OXB Stock News HeadlinesUK's Oxford Biomedica maintains annual outlookJuly 28, 2025 | reuters.comInsider Spends UK£37k Buying More Shares In Oxford BiomedicaJune 25, 2025 | finance.yahoo.comWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.August 2 at 2:00 AM | InvestorPlace (Ad)Oxford Biomedica completes acquisition of remaining stake in U.S. subsidiaryJune 24, 2025 | finance.yahoo.comOxford Biomedica announces executive share option grantsMay 17, 2025 | uk.investing.comOxford BioMedica PLC OXBMay 7, 2025 | morningstar.comMOxford Biomedica insider completes share transactionMay 2, 2025 | uk.investing.comOxford Biomedica reports FY24 EPS (GPB 41.75) vs. (GPB 163.11) last yearApril 9, 2025 | msn.comSee More Headlines OXB Stock Analysis - Frequently Asked Questions How have OXB shares performed this year? Oxford Biomedica's stock was trading at GBX 420 at the beginning of the year. Since then, OXB shares have increased by 10.6% and is now trading at GBX 464.50. How were Oxford Biomedica's earnings last quarter? Oxford Biomedica plc (LON:OXB) released its earnings results on Wednesday, April, 9th. The biopharmaceutical company reported ($41.75) earnings per share for the quarter. Oxford Biomedica had a negative trailing twelve-month return on equity of 202.50% and a negative net margin of 145.98%. Read the conference call transcript. How do I buy shares of Oxford Biomedica? Shares of OXB stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of Oxford Biomedica own? Based on aggregate information from My MarketBeat watchlists, some other companies that Oxford Biomedica investors own include EnQuest (ENQ), Petra Diamonds (PDL), Sirius Minerals (SXX), Centamin (CEY), Lloyds Banking Group (LLOY), Oxford BioMedica (OXBDF) and Barclays (BARC). Company Calendar Last Earnings4/09/2025Today8/02/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:OXB CIKN/A Webwww.oxfordbiomedica.co.uk Phone+44-1865-783000FaxN/AEmployees891Year FoundedN/APrice Target and Rating Average Price Target for Oxford BiomedicaGBX 390 High Price TargetGBX 400 Low Price TargetGBX 380 Potential Upside/Downside-16.0%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)GBX (134.59) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-£143.51 million Net Margins-145.98% Pretax MarginN/A Return on Equity-202.50% Return on Assets-12.67% Debt Debt-to-Equity Ratio166.48 Current Ratio2.35 Quick Ratio1.67 Sales & Book Value Annual Sales£98.31 million Price / Sales5.02 Cash FlowGBX 154.50 per share Price / Cash Flow3.01 Book ValueGBX 67.70 per share Price / Book6.86Miscellaneous Outstanding Shares106,301,077Free FloatN/AMarket Cap£493.77 million OptionableNot Optionable Beta1.09 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (LON:OXB) was last updated on 8/2/2025 by MarketBeat.com Staff From Our Partners379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | SponsoredAlien rocks potentially worth trillions…It might look like just a weird rock—but it’s tied to a discovery 60 Minutes says could be worth up to $16 tri...Porter & Company | SponsoredTrump’s crypto advisor may have revealed the next big crypto opportunityWhile investors chase Bitcoin toward $100K, D.C. insiders are quietly loading up on something else. One of Tru...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Oxford Biomedica plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Oxford Biomedica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.